首页 > 最新文献

Indian Journal of Medical Microbiology最新文献

英文 中文
Invasive aspergillosis due to cryptic Aspergillus species: A prospective study from a single centre in India 由隐匿曲霉菌种引起的侵袭性曲霉病:印度一家中心的前瞻性研究。
IF 1.4 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-23 DOI: 10.1016/j.ijmmb.2024.100708
R. Sruti Janani, Immaculata Xess, Bimal Kumar Das, Saumya Cs, Tamanna Bordoloi, Mragnayani Pandey, Jaweed Ahmed, Gagandeep Singh

Background

& objective: The existence of visually identical cryptic Aspergillus species that can be distinguished only by molecular techniques is becoming more widely acknowledged. For the majority of antifungal drugs, these are known to exhibit a greater minimal inhibitory concentration in vitro. For the purpose of receiving the proper care, it is crucial to identify these species at right time. Our aim in this work is to identify and describe the Aspergillus species that are cryptic from all of the clinical samples.

Methods

Routine samples from inpatients and outpatients received in department of Microbiology, All India Institute of Medical Sciences, New Delhi, showing growth of Aspergillus species were included in this study. Phenotypic and Matrix Assisted Laser Desorption Ionisation - Time of Flight identified isolates were analysed for cryptic species, by PCR and ITS/ß – tubulin sequencing. In accordance with CLSI recommendations, antifungal susceptibility testing was conducted using micro broth dilution.

Results

Of the 94 isolates, 54 A. fumigatus, 34 A. flavus, 3 A. nidulans, 2 A. terreus, and 1 A. niger were morphologically identified. MALDI-TOF misidentified 2 A. nidulans isolates and 1 A, stellatus isolate. The ß – tubulin sequence analysis revealed that 2 isolates (2.08 %) were cryptic, one was A. stellatus and another one was A. tubingensis.

背景:及目的:人们越来越广泛地认识到,存在着视觉上完全相同、但只能通过分子技术才能区分的隐蔽曲霉菌种。对于大多数抗真菌药物来说,这些菌种在体外表现出更高的最小抑菌浓度。为了得到适当的治疗,及时识别这些菌种至关重要。我们这项工作的目的是鉴定和描述所有临床样本中隐匿的曲霉菌种:方法:新德里全印度医学科学研究所微生物学系接收的住院和门诊患者的常规样本中均有曲霉菌生长。通过 PCR 和 ITS/ß - 微管蛋白测序,对表型和基质辅助激光解吸电离-飞行时间鉴定出的分离物进行了隐性物种分析。根据 CLSI 建议,采用微肉汤稀释法进行了抗真菌药敏试验:结果:在 94 个分离物中,54 个烟曲霉菌、34 个黄曲霉菌、3 个尼杜兰菌、2 个赤霉菌和 1 个黑曲霉菌经形态鉴定。MALDI-TOF 错误鉴定了 2 个 A. nidulans 分离物和 1 个 A. stellatus 分离物。ß - 管蛋白序列分析表明,有 2 个分离物(2.08 %)是隐性的,一个是 A. stellatus,另一个是 A. tubingensis。
{"title":"Invasive aspergillosis due to cryptic Aspergillus species: A prospective study from a single centre in India","authors":"R. Sruti Janani,&nbsp;Immaculata Xess,&nbsp;Bimal Kumar Das,&nbsp;Saumya Cs,&nbsp;Tamanna Bordoloi,&nbsp;Mragnayani Pandey,&nbsp;Jaweed Ahmed,&nbsp;Gagandeep Singh","doi":"10.1016/j.ijmmb.2024.100708","DOIUrl":"10.1016/j.ijmmb.2024.100708","url":null,"abstract":"<div><h3>Background</h3><p><u>&amp; objective</u>: The existence of visually identical cryptic <em>Aspergillus</em> species that can be distinguished only by molecular techniques is becoming more widely acknowledged. For the majority of antifungal drugs, these are known to exhibit a greater minimal inhibitory concentration in vitro. For the purpose of receiving the proper care, it is crucial to identify these species at right time. Our aim in this work is to identify and describe the <em>Aspergillus</em> species that are cryptic from all of the clinical samples.</p></div><div><h3>Methods</h3><p>Routine samples from inpatients and outpatients received in department of Microbiology, All India Institute of Medical Sciences, New Delhi, showing growth of <em>Aspergillus</em> species were included in this study. Phenotypic and Matrix Assisted Laser Desorption Ionisation - Time of Flight identified isolates were analysed for cryptic species, by PCR and ITS/<em>ß</em> – tubulin sequencing. In accordance with CLSI recommendations, antifungal susceptibility testing was conducted using micro broth dilution.</p></div><div><h3>Results</h3><p>Of the 94 isolates, 54 <em>A. fumigatus</em>, 34 <em>A. flavus</em>, 3 <em>A. nidulans</em>, 2 <em>A. terreus,</em> and 1 <em>A. niger</em> were morphologically identified. MALDI-TOF misidentified 2 <em>A. nidulans</em> isolates and 1 <em>A, stellatus</em> isolate. The <em>ß</em> – tubulin sequence analysis revealed that 2 isolates (2.08 %) were cryptic, one was <em>A. stellatus</em> and another one was <em>A. tubingensis</em>.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100708"},"PeriodicalIF":1.4,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unmasking a looming crisis: Escalating MIC of last resort drugs against MRSA isolates from a tertiary care hospital in Central India "揭开迫在眉睫的危机:印度中部一家三甲医院针对 MRSA 分离物的最后手段药物的 MIC 不断升级"。
IF 1.4 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-21 DOI: 10.1016/j.ijmmb.2024.100707
Neha S. Bawankar , Gopal N. Agrawal, Sunanda S. Zodpey (Shrikhande)

Purpose

The Centers for Disease Control and Prevention has classified methicillin-resistant S aureus (MRSA) as a serious public health threat. The escalating minimum inhibitory concentration (MIC) of standard anti-methicillin-resistant S aureus (MRSA) drugs within the susceptible range, known as "MIC creep," jeopardizes their effectiveness against MRSA infections, posing additional challenges in managing MRSA infections. This cross-sectional study was conducted in a tertiary care hospital in Central India to assess the susceptibility trends of clinical MRSA isolates against commonly used anti-MRSA drugs and to observe MIC creep, if any, over three years (2020–2022).

Methods

The study included 158 non-repetitive clinical MRSA isolates. The MICs of vancomycin, teicoplanin, and linezolid were determined in MRSA strains using agar dilution, while the MIC of daptomycin was performed by broth microdilution. MIC creep was assessed by calculating MIC50, MIC90, Modal MIC, G-mean MIC, and susceptible and resistant percentages for the fiscal years 2020, 2021, and 2022.

Results

Of the 158 MRSA isolates, none were resistant to vancomycin, teicoplanin, and daptomycin, but two showed resistance to linezolid (LRSA). However, fifteen isolates showed intermediate resistance to vancomycin (VISA), and five showed intermediate resistance to teicoplanin (TISA). MIC of these anti-MRSA drugs increased in 2021 and 2022 compared to 2020. G-mean MIC for vancomycin, teicoplanin, and linezolid in MRSA strains increased significantly over the study period, while daptomycin MIC remained relatively stable, with a slight increase in 2021 and 2022. There was a high resistance rate for clindamycin, doxycycline, and chloramphenicol among VISA, TISA, and LRSA isolates compared to MRSA.

Conclusions

During the three years of the study, “MIC creep” was observed in vancomycin, teicoplanin, and linezolid and, to some extent, for daptomycin in MRSA strains. The recovery of VISA, TISA, and linezolid-resistant MRSAs is worrisome, suggesting possible MRSA treatment failure and being a forerunner of resistant strains.

目的:美国疾病控制和预防中心已将耐甲氧西林金黄色葡萄球菌(MRSA)列为严重的公共卫生威胁。标准抗耐甲氧西林金黄色葡萄球菌(MRSA)药物在易感范围内的最低抑菌浓度(MIC)不断升高,即所谓的 "MIC爬升",损害了这些药物对 MRSA 感染的有效性,给 MRSA 感染的管理带来了更多挑战。这项横断面研究在印度中部的一家三级医院进行,目的是评估临床 MRSA 分离物对常用抗 MRSA 药物的敏感性趋势,并观察三年内(2020-2022 年)是否存在 MIC 爬升:研究包括 158 个非重复性临床 MRSA 分离物。采用琼脂稀释法测定万古霉素、替考拉宁和利奈唑胺在MRSA菌株中的MIC,采用肉汤微量稀释法测定达托霉素的MIC。通过计算2020、2021和2022财政年度的MIC50、MIC90、MIC模数、MIC平均值以及易感和耐药百分比,对MIC爬升情况进行了评估:在 158 个 MRSA 分离物中,没有一个对万古霉素、替考拉宁和达托霉素产生耐药性,但有两个对利奈唑胺(LRSA)产生了耐药性。然而,15 个分离株对万古霉素(VISA)表现出中间耐药性,5 个分离株对替考拉宁(TISA)表现出中间耐药性。与 2020 年相比,2021 年和 2022 年这些抗 MRSA 药物的 MIC 均有所上升。在研究期间,万古霉素、替考拉宁和利奈唑胺在MRSA菌株中的G-平均MIC显著增加,而达托霉素的MIC相对稳定,2021年和2022年略有增加。与MRSA相比,VISA、TISA和LRSA分离株对克林霉素、强力霉素和氯霉素的耐药率较高:在三年的研究过程中,观察到万古霉素、替考拉宁和利奈唑胺的 "MIC爬升",在一定程度上,MRSA菌株中的达托霉素也出现了 "MIC爬升"。对 VISA、TISA 和利奈唑胺耐药的 MRSA 的恢复令人担忧,这表明 MRSA 的治疗可能失败,并可能成为耐药菌株的先驱。
{"title":"Unmasking a looming crisis: Escalating MIC of last resort drugs against MRSA isolates from a tertiary care hospital in Central India","authors":"Neha S. Bawankar ,&nbsp;Gopal N. Agrawal,&nbsp;Sunanda S. Zodpey (Shrikhande)","doi":"10.1016/j.ijmmb.2024.100707","DOIUrl":"10.1016/j.ijmmb.2024.100707","url":null,"abstract":"<div><h3>Purpose</h3><p>The Centers for Disease Control and Prevention has classified methicillin-resistant <em>S aureus</em> (MRSA) as a serious public health threat. The escalating minimum inhibitory concentration (MIC) of standard anti-methicillin-resistant <em>S aureus</em> (MRSA) drugs within the susceptible range, known as \"MIC creep,\" jeopardizes their effectiveness against MRSA infections, posing additional challenges in managing MRSA infections. This cross-sectional study was conducted in a tertiary care hospital in Central India to assess the susceptibility trends of clinical MRSA isolates against commonly used anti-MRSA drugs and to observe MIC creep, if any, over three years (2020–2022).</p></div><div><h3>Methods</h3><p>The study included 158 non-repetitive clinical MRSA isolates. The MICs of vancomycin, teicoplanin, and linezolid were determined in MRSA strains using agar dilution, while the MIC of daptomycin was performed by broth microdilution. MIC creep was assessed by calculating MIC50, MIC90, Modal MIC, G-mean MIC, and susceptible and resistant percentages for the fiscal years 2020, 2021, and 2022.</p></div><div><h3>Results</h3><p>Of the 158 MRSA isolates, none were resistant to vancomycin, teicoplanin, and daptomycin, but two showed resistance to linezolid (LRSA). However, fifteen isolates showed intermediate resistance to vancomycin (VISA), and five showed intermediate resistance to teicoplanin (TISA). MIC of these anti-MRSA drugs increased in 2021 and 2022 compared to 2020. G-mean MIC for vancomycin, teicoplanin, and linezolid in MRSA strains increased significantly over the study period, while daptomycin MIC remained relatively stable, with a slight increase in 2021 and 2022. There was a high resistance rate for clindamycin, doxycycline, and chloramphenicol among VISA, TISA, and LRSA isolates compared to MRSA.</p></div><div><h3>Conclusions</h3><p>During the three years of the study, “MIC creep” was observed in vancomycin, teicoplanin, and linezolid and, to some extent, for daptomycin in MRSA strains. The recovery of VISA, TISA, and linezolid-resistant MRSAs is worrisome, suggesting possible MRSA treatment failure and being a forerunner of resistant strains.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100707"},"PeriodicalIF":1.4,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of nurse: Patient ratio as a factor in hand hygiene compliance in a tertiary care hospital in North India: Perception versus reality 印度北部一家三级医院护士与病人比例对手部卫生依从性的影响:观念与现实。
IF 1.4 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-21 DOI: 10.1016/j.ijmmb.2024.100706
Manisha Biswal, Parakriti Gupta, Reet, Aakanksha Dutta, Harinder Kaur, Kulbeer Kaur, Rupinder Kaur, Manjinder Kaur, Navneet Dhaliwal, Pankaj Arora
{"title":"Role of nurse: Patient ratio as a factor in hand hygiene compliance in a tertiary care hospital in North India: Perception versus reality","authors":"Manisha Biswal,&nbsp;Parakriti Gupta,&nbsp;Reet,&nbsp;Aakanksha Dutta,&nbsp;Harinder Kaur,&nbsp;Kulbeer Kaur,&nbsp;Rupinder Kaur,&nbsp;Manjinder Kaur,&nbsp;Navneet Dhaliwal,&nbsp;Pankaj Arora","doi":"10.1016/j.ijmmb.2024.100706","DOIUrl":"10.1016/j.ijmmb.2024.100706","url":null,"abstract":"","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100706"},"PeriodicalIF":1.4,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aptamer and aptasensor technology for diagnosis of infectious diseases: A mini review 用于诊断传染病的肽聚体和肽传感器技术:小型综述。
IF 1.4 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-17 DOI: 10.1016/j.ijmmb.2024.100694
Radhika K. Madalgi , Suresh B. Arakera , Raghavendra D. Kulkarni

Background

Aptamers are not so new a concept, however, it is scarcely discussed by medical fraternity. Aptamers are potent, new identification molecules set to rope in a new technique in the diagnostic arena. Aptamers have started almost a revolution in diagnostic assays since their discovery in the 90s. (Radu S. Current and previous disease outbreaks around the world, U.S. News & World Report. 2020 Mar 13 [cited 2024 Jun 17]. Available from: https://www.usnews.com/news/best-countries/slideshows/20-pandemic-and-epidemic-diseases-according-to-who) provides an overview of pandemics and epidemics as reported by the WHO. It is interesting to note that several endemic and epidemic diseases viz. Chikungunya, Cholera, Crimean-Congo haemorrhagic fever, Ebola virus disease, Hendra virus infection, Influenza, Lassa fever, Marburg virus disease, Meningitis, MERS-CoV (Middle East Respiratory Syndrome Corona Virus), Monkeypox, Nipah virus infection, Novel coronavirus, Plague, Rift Valley fever, SARS (Severe Acute Respiratory Syndrome), Smallpox, Tularaemia, Yellow fever, and Zika virus disease have been identified by the WHO and are being explored for applicability of aptamer technology in their identification.

Objectives

One of the most important necessities to control epidemic or pandemic diseases is early diagnosis. However, the majority of the diagnostic tests for these diseases are available only in tertiary care centres. The objective of this review is to discuss the potential of aptamer technology to provide undemanding, simple, specific, sensitive, and cost-effective diagnostic assays that are useable in remote and field conditions.

Content

Here, we discuss recent advances and approaches in aptamer and aptamer engineering useful in the diagnosis of infectious and non-infectious conditions. This review also discusses a few sensing discoveries which are a gift of advanced engineering and technology using optical and electrochemical aptasensors. It's still a long way to go, and we need to take into account the technological challenges being faced by aptamer-aptasensor technology.

背景:金黄色葡萄球菌(Aptamers)并不是一个新概念,但医学界对它的讨论却少之又少。适配体是一种强效的新型鉴定分子,将为诊断领域带来一项新技术。自上世纪 90 年代被发现以来,Aptamers 几乎掀起了一场诊断测定的革命。 Radu S. 当前和以往全球爆发的疾病,《美国新闻与世界报道》。2020 年 3 月 13 日 [2024 年 6 月 17 日引用]。见 https://www.usnews.com/news/best-countries/slideshows/20-pandemic-and-epidemic-diseases-according-to-who)提供了世界卫生组织报告的大流行病和流行病概况。值得注意的是,有几种地方病和流行病,即基孔肯雅病、霍乱和疟疾。基孔肯雅病、霍乱、克里米亚-刚果出血热、埃博拉病毒病、亨德拉病毒感染、流感、拉沙热、马尔堡病毒病、脑膜炎、MERS-CoV(中东呼吸综合征冠状病毒)、猴痘、尼帕病毒感染、新型冠状病毒、鼠疫、裂谷热、SARS(严重急性呼吸系统综合症)、天花、土拉菌病、黄热病和寨卡病毒病已被世卫组织确定,目前正在探索是否可将适配体技术用于确定这些疾病。目标:控制流行病或大流行病最重要的必要条件之一是早期诊断。然而,这些疾病的大多数诊断检测只能在三级医疗中心进行。本综述的目的是讨论适配体技术的潜力,以提供可在偏远地区和野外条件下使用的无要求、简单、特异、灵敏和具有成本效益的诊断检测方法:在此,我们将讨论在诊断感染性和非感染性病症方面,适配体和适配体工程的最新进展和方法。这篇综述还讨论了利用光学和电化学适配体的先进工程和技术所带来的一些传感发现。我们还有很长的路要走,我们需要考虑到适配体-传感器技术所面临的技术挑战。
{"title":"Aptamer and aptasensor technology for diagnosis of infectious diseases: A mini review","authors":"Radhika K. Madalgi ,&nbsp;Suresh B. Arakera ,&nbsp;Raghavendra D. Kulkarni","doi":"10.1016/j.ijmmb.2024.100694","DOIUrl":"10.1016/j.ijmmb.2024.100694","url":null,"abstract":"<div><h3>Background</h3><p>Aptamers are not so new a concept, however, it is scarcely discussed by medical fraternity. Aptamers are potent, new identification molecules set to rope in a new technique in the diagnostic arena. Aptamers have started almost a revolution in diagnostic assays since their discovery in the 90s. (Radu S. Current and previous disease outbreaks around the world, U.S. News &amp; World Report. 2020 Mar 13 [cited 2024 Jun 17]. Available from: <span><span>https://www.usnews.com/news/best-countries/slideshows/20-pandemic-and-epidemic-diseases-according-to-who</span><svg><path></path></svg></span>) provides an overview of pandemics and epidemics as reported by the WHO. It is interesting to note that several endemic and epidemic diseases viz. Chikungunya, Cholera, Crimean-Congo haemorrhagic fever, Ebola virus disease, Hendra virus infection, Influenza, Lassa fever, Marburg virus disease, Meningitis, MERS-CoV (Middle East Respiratory Syndrome Corona Virus), Monkeypox, Nipah virus infection, Novel coronavirus, Plague, Rift Valley fever, SARS (Severe Acute Respiratory Syndrome), Smallpox, Tularaemia, Yellow fever, and Zika virus disease have been identified by the WHO and are being explored for applicability of aptamer technology in their identification.</p></div><div><h3>Objectives</h3><p>One of the most important necessities to control epidemic or pandemic diseases is early diagnosis. However, the majority of the diagnostic tests for these diseases are available only in tertiary care centres. The objective of this review is to discuss the potential of aptamer technology to provide undemanding, simple, specific, sensitive, and cost-effective diagnostic assays that are useable in remote and field conditions.</p></div><div><h3>Content</h3><p>Here, we discuss recent advances and approaches in aptamer and aptamer engineering useful in the diagnosis of infectious and non-infectious conditions. This review also discusses a few sensing discoveries which are a gift of advanced engineering and technology using optical and electrochemical aptasensors. It's still a long way to go, and we need to take into account the technological challenges being faced by aptamer-aptasensor technology.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100694"},"PeriodicalIF":1.4,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human monkeypox virus: A systematic critical review during the pandemic peak 人类猴痘病毒:大流行高峰期的系统性关键审查。
IF 1.4 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-14 DOI: 10.1016/j.ijmmb.2024.100704
Neama Derhab

Background

In July 2022, the world health organization (WHO) announced the monkeypox virus (MPXV) as a public health emergency of international concern, due to the unprecedented global transmission of the disease beyond previously endemic countries in Africa.

Methods

For this systematic review, the author searched the “web of science” (WoS) database, which retrieves 138 articles on MPXV, published between 01-04–2022 and 22-09-2022. This period witnessed the maximum cases of infection as confirmed by the WHO. Seventy articles were used for in-depth analysis, after excluding papers not highly relevant to the topic.

Results and conclusions

The current review demonstrates different types of MPXV identification analysis, transmission of MPXV, clinical features, immune responses against MPXV, the mutations, and phylogenetic analysis. It also identifies the patients with high-risk complications and determines the other diseases related to MPXV. This paper provides suggestions for the suitable usage of vaccines or antiviral drugs as a procedure to control the outbreak and preventive strategies related to the humans. This research discusses significant implications and recommendations to contribute in reducing the spread of MPXV and presents avenues for upcoming MPXV research.

背景:2022年7月,世界卫生组织(WHO)宣布猴痘病毒(MPXV)为国际关注的突发公共卫生事件,原因是该疾病在非洲以前流行的国家之外出现了前所未有的全球传播:作者在 "web of science"(WoS)数据库中检索了 138 篇关于 MPXV 的文章,这些文章发表于 2022 年 4 月 1 日至 2022 年 9 月 22 日之间。这一时期是世卫组织确认的感染病例最多的时期。在剔除了与该主题不太相关的文章后,有 70 篇文章被用于深入分析:本综述展示了不同类型的 MPXV 鉴定分析、MPXV 传播、临床特征、针对 MPXV 的免疫反应、突变和系统发育分析。它还识别了高危并发症患者,并确定了与 MPXV 相关的其他疾病。本文就适当使用疫苗或抗病毒药物作为控制疫情的程序以及与人类相关的预防策略提出了建议。本研究讨论了有助于减少 MPXV 传播的重要意义和建议,并为即将开展的 MPXV 研究提供了途径。
{"title":"Human monkeypox virus: A systematic critical review during the pandemic peak","authors":"Neama Derhab","doi":"10.1016/j.ijmmb.2024.100704","DOIUrl":"10.1016/j.ijmmb.2024.100704","url":null,"abstract":"<div><h3>Background</h3><p>In July 2022, the world health organization (WHO) announced the monkeypox virus (MPXV) as a public health emergency of international concern, due to the unprecedented global transmission of the disease beyond previously endemic countries in Africa.</p></div><div><h3>Methods</h3><p>For this systematic review, the author searched the “web of science” (WoS) database, which retrieves 138 articles on MPXV, published between 01-04–2022 and 22-09-2022. This period witnessed the maximum cases of infection as confirmed by the WHO. Seventy articles were used for in-depth analysis, after excluding papers not highly relevant to the topic.</p></div><div><h3>Results and conclusions</h3><p>The current review demonstrates different types of MPXV identification analysis, transmission of MPXV, clinical features, immune responses against MPXV, the mutations, and phylogenetic analysis. It also identifies the patients with high-risk complications and determines the other diseases related to MPXV. This paper provides suggestions for the suitable usage of vaccines or antiviral drugs as a procedure to control the outbreak and preventive strategies related to the humans. This research discusses significant implications and recommendations to contribute in reducing the spread of MPXV and presents avenues for upcoming MPXV research.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100704"},"PeriodicalIF":1.4,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends of drug resistance in M. tuberculosis in a reference laboratory in Central India: Forging ahead towards TB elimination 印度中部参考实验室结核杆菌的耐药性趋势:向消灭结核病迈进。
IF 1.4 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-14 DOI: 10.1016/j.ijmmb.2024.100701
Prabha Desikan , Nikita Panwalkar , Aseem Rangnekar , Zeba Khan , Ram Prakash Punde , Arun Kumar Sharma , Ragini Kushwaha , Chinnaiyan Ponnuraja , Sridhar Anand

Purpose

The National Tuberculosis Elimination Programme (NTEP) of the Government of India has strived to control tuberculosis (TB) in the country through various interventions. Understanding the trends of resistance patterns may provide insights into the effectiveness of TB control activities in the country.

Methods

A total of 31,144 clinical samples were received from 2013 to 2022 from presumptive drug-resistant TB patients. All the specimens were decontaminated and subjected to the line probe assay for detection of resistance to rifampicin and isoniazid. Mycobacterium tuberculosis (MTB) was detected in 28,814 samples. Autoregressive integrated moving average model (ARIMA) was fitted to assess the trend over time.

Results

A decreasing trend in multi-drug resistant TB from 19 % in 2013 to 4 % in 2022 was seen. A decreasing trend in rifampicin monoresistance from 11.2 % in 2013 to 1.5 % in 2022 was seen, though there was an increase in resistance in 2017. No significant decreasing trends were seen in the proportion of isoniazid monoresistance from 8.3 % in 2013 to 7 % in 2022.

Conclusion

The findings are encouraging, and to a considerable extent, affirm that India is well on track with regard to the goal of TB elimination.

目的:印度政府的国家消除结核病计划(NTEP)一直在努力通过各种干预措施控制该国的结核病(TB)。了解耐药性模式的趋势有助于深入了解该国结核病控制活动的有效性:从 2013 年到 2022 年,共收到 31,144 份临床样本,这些样本来自推定耐药的肺结核患者。所有样本都经过净化,并采用线探针检测法检测对利福平和异烟肼的耐药性。在 28,814 份样本中检测到了结核分枝杆菌(MTB)。采用自回归综合移动平均模型(ARIMA)评估随时间变化的趋势:耐多药结核病呈下降趋势,从 2013 年的 19% 降至 2022 年的 4%。利福平单耐药率呈下降趋势,从2013年的11.2%降至2022年的1.5%,但2017年耐药率有所上升。异烟肼单耐药性的比例从2013年的8.3%下降到2022年的7%,但没有明显的下降趋势:研究结果令人鼓舞,在很大程度上证明印度在实现消除结核病的目标方面进展顺利。
{"title":"Trends of drug resistance in M. tuberculosis in a reference laboratory in Central India: Forging ahead towards TB elimination","authors":"Prabha Desikan ,&nbsp;Nikita Panwalkar ,&nbsp;Aseem Rangnekar ,&nbsp;Zeba Khan ,&nbsp;Ram Prakash Punde ,&nbsp;Arun Kumar Sharma ,&nbsp;Ragini Kushwaha ,&nbsp;Chinnaiyan Ponnuraja ,&nbsp;Sridhar Anand","doi":"10.1016/j.ijmmb.2024.100701","DOIUrl":"10.1016/j.ijmmb.2024.100701","url":null,"abstract":"<div><h3>Purpose</h3><p>The National Tuberculosis Elimination Programme (NTEP) of the Government of India has strived to control tuberculosis (TB) in the country through various interventions. Understanding the trends of resistance patterns may provide insights into the effectiveness of TB control activities in the country.</p></div><div><h3>Methods</h3><p>A total of 31,144 clinical samples were received from 2013 to 2022 from presumptive drug-resistant TB patients. All the specimens were decontaminated and subjected to the line probe assay for detection of resistance to rifampicin and isoniazid. <em>Mycobacterium tuberculosis</em> (MTB) was detected in 28,814 samples. Autoregressive integrated moving average model (ARIMA) was fitted to assess the trend over time.</p></div><div><h3>Results</h3><p>A decreasing trend in multi-drug resistant TB from 19 % in 2013 to 4 % in 2022 was seen. A decreasing trend in rifampicin monoresistance from 11.2 % in 2013 to 1.5 % in 2022 was seen, though there was an increase in resistance in 2017. No significant decreasing trends were seen in the proportion of isoniazid monoresistance from 8.3 % in 2013 to 7 % in 2022.</p></div><div><h3>Conclusion</h3><p>The findings are encouraging, and to a considerable extent, affirm that India is well on track with regard to the goal of TB elimination.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100701"},"PeriodicalIF":1.4,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent pyogenic brain abscess in immunocompetent patient by Bacteroides fragilis: A silent cause of concern 由脆弱拟杆菌引起的免疫功能正常患者的复发性化脓性脑脓肿:令人担忧的隐患
IF 1.4 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-14 DOI: 10.1016/j.ijmmb.2024.100702
Sonu Kumari Agrawal , Tanu Sagar , P Sarat Chandra , Rama Chaudhry

Anaerobic bacteria are rare but important cause of otogenic brain abscess. Improved patient management techniques and early clinical and laboratory diagnosis of otogenic infections are necessary to reduce the risk of intracranial complications. Here we present a case of recurrent pyogenic brain abscess caused by Bacteroides fragilis secondary to otitis media.

厌氧菌是耳源性脑脓肿的罕见但重要的病因。要降低颅内并发症的风险,就必须改进患者管理技术,及早进行耳源性感染的临床和实验室诊断。在此,我们介绍一例由脆弱拟杆菌继发中耳炎引起的复发性化脓性脑脓肿病例。
{"title":"Recurrent pyogenic brain abscess in immunocompetent patient by Bacteroides fragilis: A silent cause of concern","authors":"Sonu Kumari Agrawal ,&nbsp;Tanu Sagar ,&nbsp;P Sarat Chandra ,&nbsp;Rama Chaudhry","doi":"10.1016/j.ijmmb.2024.100702","DOIUrl":"10.1016/j.ijmmb.2024.100702","url":null,"abstract":"<div><p>Anaerobic bacteria are rare but important cause of otogenic brain abscess. Improved patient management techniques and early clinical and laboratory diagnosis of otogenic infections are necessary to reduce the risk of intracranial complications. Here we present a case of recurrent pyogenic brain abscess caused by <em>Bacteroides fragilis</em> secondary to otitis media.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100702"},"PeriodicalIF":1.4,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141912446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Burden of drug-resistant tuberculosis by the GeneXpert MTB/RIF assay and its clinico-epidemiological aspects at a tertiary care hospital in West Bengal 西孟加拉邦一家三级甲等医院采用 GeneXpert MTB/RIF 检测法检测耐药结核病的负担及其临床流行病学方面的问题。
IF 1.4 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-14 DOI: 10.1016/j.ijmmb.2024.100703
Nupur Pal , Raja Ray , Somenath Kundu , Avijit Hazra , Singdha Sau , Suhita Sur , Shreya Saha , Wasim Mallick

Multidrug -resistant tuberculosis (MDRTB) is a serious threat to mankind. India has the highest number of MDRTB cases, although majority remain undiagnosed due to inadequate diagnostic infrastructure, leading to increased community transmission and mortality. This one-year observational retrospective study highlighted the effectiveness of the National Tuberculosis Elimination Program (NTEP) for prompt detection of drug-resistant TB by GeneXpert MTB/RIF assay and revealed its associated clinico-epidemiological factors. The overall detection rates of MTB and RRTB were 20.70 % and 20.86 % respectively. The pediatric population had 7.69 % rifampicin resistance, and HIV was strongly associated with the development of TB and RRTB (P < 0.01).

耐多药结核病(MDRTB)是对人类的严重威胁。印度是耐多药结核病例最多的国家,但由于诊断基础设施不足,大多数病例仍未得到诊断,导致社区传播和死亡率上升。这项为期一年的观察性回顾研究强调了国家消除结核病计划(NTEP)通过 GeneXpert MTB/RIF 检测法及时发现耐药结核病的有效性,并揭示了与之相关的临床流行病学因素。MTB 和 RRTB 的总体检出率分别为 20.70% 和 20.86%。儿科人群的利福平耐药率为 7.69%,艾滋病毒与结核病和 RRTB 的发生密切相关(P<0.05)。
{"title":"Burden of drug-resistant tuberculosis by the GeneXpert MTB/RIF assay and its clinico-epidemiological aspects at a tertiary care hospital in West Bengal","authors":"Nupur Pal ,&nbsp;Raja Ray ,&nbsp;Somenath Kundu ,&nbsp;Avijit Hazra ,&nbsp;Singdha Sau ,&nbsp;Suhita Sur ,&nbsp;Shreya Saha ,&nbsp;Wasim Mallick","doi":"10.1016/j.ijmmb.2024.100703","DOIUrl":"10.1016/j.ijmmb.2024.100703","url":null,"abstract":"<div><p>Multidrug -resistant tuberculosis (MDRTB) is a serious threat to mankind. India has the highest number of MDRTB cases, although majority remain undiagnosed due to inadequate diagnostic infrastructure, leading to increased community transmission and mortality. This one-year observational retrospective study highlighted the effectiveness of the National Tuberculosis Elimination Program (NTEP) for prompt detection of drug-resistant TB by GeneXpert MTB/RIF assay and revealed its associated clinico-epidemiological factors. The overall detection rates of MTB and RRTB were 20.70 % and 20.86 % respectively. The pediatric population had 7.69 % rifampicin resistance, and HIV was strongly associated with the development of TB and RRTB (P &lt; 0.01).</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100703"},"PeriodicalIF":1.4,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synergy testing of ceftazidime-avibactam and aztreonam combination by two different methods 采用两种不同方法对头孢唑肟-阿维菌素和阿奇霉素复方制剂进行协同作用试验。
IF 1.4 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-14 DOI: 10.1016/j.ijmmb.2024.100705
Ekadashi Rajni, Kriti Goyal, Kanika R. Bairwa
{"title":"Synergy testing of ceftazidime-avibactam and aztreonam combination by two different methods","authors":"Ekadashi Rajni,&nbsp;Kriti Goyal,&nbsp;Kanika R. Bairwa","doi":"10.1016/j.ijmmb.2024.100705","DOIUrl":"10.1016/j.ijmmb.2024.100705","url":null,"abstract":"","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100705"},"PeriodicalIF":1.4,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of dried blood spots in the detection of coronavirus disease 2019 (COVID-19): A systematic review 使用干血斑检测 2019 年冠状病毒病 (COVID-19):系统综述。
IF 1.4 4区 医学 Q4 IMMUNOLOGY Pub Date : 2024-08-13 DOI: 10.1016/j.ijmmb.2024.100700
Jannie Nikolai M. Alquero , Patrizia Marie S. Estanislao , Svethlana Marie M. Hermino , Ranna Duben M. Manding , Joshua Euchie D. Robles , Christene Mae A. Canillo , Ourlad Alzeus G. Tantengco

Introduction

COVID-19 disease continues to be a global health concern. The current protocol for detecting SARS-CoV-2 requires healthcare professionals to draw blood from patients. Recent studies showed that dried blood spot (DBS) is a valuable sampling procedure that can collect a low blood volume without the need for the presence of medical practitioners. This study synthesized the available literature on using DBS as a blood collection tool to diagnose COVID-19 disease.

Materials and methods

A comprehensive search utilizing OVID, CINAHL, and Scopus databases was done from inception to March 2023. Five reviewers collected, extracted and organized the study data.

Results

This systematic review included 57 articles. DBS was commonly prepared by finger pricking. Most studies showed more favorable results and longer sample stability (more than 1080 days) with lower storage temperature conditions for the DBS. DBS samples were mostly used for serological assays for COVID-19 disease detection. ELISA was the most used detection method (43.66 %). Diagnostic performance of laboratory tests for COVID-19 using DBS sample showed high sensitivity of up to 100 % for immunoassay tests and 100 % specificity in agglutination, PCR, and DELFIA assays.

Conclusion

DBS sampling coupled with serological testing can be an alternative method for collecting blood and detecting COVID-19 disease. These tests using DBS samples showed excellent diagnostic performance across various geographic locations and demographics.

导言:COVID-19 疾病仍然是全球关注的健康问题。目前检测 SARS-CoV-2 的方案要求医护人员从患者身上抽血。最近的研究表明,干血斑(DBS)是一种有价值的采样方法,它可以采集少量血液,而不需要医护人员在场。本研究综述了使用干血斑作为采血工具诊断 COVID-19 疾病的现有文献:从开始到 2023 年 3 月,利用 OVID、CINAHL 和 Scopus 数据库进行了全面检索。五位审稿人收集、提取并整理了研究数据:本系统性综述共纳入 57 篇文章。DBS 通常采用手指刺穿法进行准备。大多数研究表明,在较低的储存温度条件下,DBS 的效果更佳,样本稳定性更长(超过 1080 天)。DBS 样本大多用于 COVID-19 疾病的血清学检测。ELISA 是使用最多的检测方法(43.66%)。使用 DBS 样本进行 COVID-19 实验室检测的诊断性能显示,免疫测定的灵敏度高达 100%,凝集、PCR 和 DELFIA 检测的特异性也达到 100%:结论:DBS 抽样与血清学检测相结合,可作为采集血液和检测 COVID-19 疾病的替代方法。这些使用 DBS 样本进行的检测在不同的地理位置和人口统计中都显示出了卓越的诊断性能。
{"title":"Use of dried blood spots in the detection of coronavirus disease 2019 (COVID-19): A systematic review","authors":"Jannie Nikolai M. Alquero ,&nbsp;Patrizia Marie S. Estanislao ,&nbsp;Svethlana Marie M. Hermino ,&nbsp;Ranna Duben M. Manding ,&nbsp;Joshua Euchie D. Robles ,&nbsp;Christene Mae A. Canillo ,&nbsp;Ourlad Alzeus G. Tantengco","doi":"10.1016/j.ijmmb.2024.100700","DOIUrl":"10.1016/j.ijmmb.2024.100700","url":null,"abstract":"<div><h3>Introduction</h3><p>COVID-19 disease continues to be a global health concern. The current protocol for detecting SARS-CoV-2 requires healthcare professionals to draw blood from patients. Recent studies showed that dried blood spot (DBS) is a valuable sampling procedure that can collect a low blood volume without the need for the presence of medical practitioners. This study synthesized the available literature on using DBS as a blood collection tool to diagnose COVID-19 disease.</p></div><div><h3>Materials and methods</h3><p>A comprehensive search utilizing OVID, CINAHL, and Scopus databases was done from inception to March 2023. Five reviewers collected, extracted and organized the study data.</p></div><div><h3>Results</h3><p>This systematic review included 57 articles. DBS was commonly prepared by finger pricking. Most studies showed more favorable results and longer sample stability (more than 1080 days) with lower storage temperature conditions for the DBS. DBS samples were mostly used for serological assays for COVID-19 disease detection. ELISA was the most used detection method (43.66 %). Diagnostic performance of laboratory tests for COVID-19 using DBS sample showed high sensitivity of up to 100 % for immunoassay tests and 100 % specificity in agglutination, PCR, and DELFIA assays.</p></div><div><h3>Conclusion</h3><p>DBS sampling coupled with serological testing can be an alternative method for collecting blood and detecting COVID-19 disease. These tests using DBS samples showed excellent diagnostic performance across various geographic locations and demographics.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100700"},"PeriodicalIF":1.4,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141912447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian Journal of Medical Microbiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1